Global Health Limited (AU:GLH)
ASX:GLH
Want to see AU:GLH full AI Analyst Report?
Top Page
Global Health Limited
(Sydney:GLH)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.07
▼(-17.78% Downside)
Action:Reiterated
Date:03/24/26
The score is held down primarily by weak financial fundamentals—ongoing losses, negative operating/free cash flow, and especially negative equity—despite improving revenue and margins. Technicals add further pressure with a weak downtrend and negative momentum indicators. Valuation provides limited support because the company is still loss-making and has no stated dividend yield.
Positive Factors
Revenue Growth Trend
Sustained revenue growth over several years shows underlying demand for GLH's SaaS, licensing and services. A rising revenue base supports scale, recurring subscription economics and long-term customer relationships, improving prospects for margin levelling and product adoption.
Negative Factors
Negative Shareholders' Equity
Persistently negative equity is a structural balance-sheet weakness that raises insolvency and refinancing risk. It limits access to debt and equity markets, constrains strategic flexibility and could force dilutive recapitalisations or covenant pressures that hamper long-term growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trend
Sustained revenue growth over several years shows underlying demand for GLH's SaaS, licensing and services. A rising revenue base supports scale, recurring subscription economics and long-term customer relationships, improving prospects for margin levelling and product adoption.
Read all positive factors
Global Health Limited (GLH) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.59M
Dividend YieldN/A
Average Volume (3M)18.95K
Price to Earnings (P/E)―
Beta (1Y)-0.10
Revenue Growth-5.76%
EPS Growth8.00%
CountryAU
Employees49
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.01
Shares Outstanding58,794,537
10 Day Avg. Volume15,411
30 Day Avg. Volume18,951
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-1.06
Price to Sales (P/S)0.46
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Global Health Limited Business Overview & Revenue Model
Company Description
Global Health Limited provides digital health solutions for the healthcare sector in Australia. It provides mental health software for psychologists and psychiatrists; and integrated software solutions for various areas of community health and hum...
How the Company Makes Money
Global Health Limited generates revenue through a combination of subscription fees for its software-as-a-service (SaaS) products, licensing fees for its healthcare technologies, and service contracts with hospitals, clinics, and other healthcare p...
Global Health Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.93M | 8.67M | 8.12M | 7.82M | 6.54M | 7.03M |
| Gross Profit | 564.77K | 2.10M | -689.94K | -2.18M | -664.00K | 812.71K |
| EBITDA | -1.23M | -793.08K | -1.77M | -7.19M | -1.69M | 57.05K |
| Net Income | -809.08K | -866.63K | -1.31M | -8.05M | -2.05M | -488.00K |
Balance Sheet | ||||||
| Total Assets | 2.12M | 2.84M | 3.08M | 3.12M | 11.03M | 9.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.04M | 1.38M | 2.07M | 2.24M | 6.38M | 4.84M |
| Total Debt | 1.63M | 1.46M | 1.03M | 44.94K | 141.83K | 304.11K |
| Total Liabilities | 6.46M | 6.58M | 5.98M | 4.74M | 4.95M | 5.00M |
| Stockholders Equity | -4.35M | -3.73M | -2.90M | -1.62M | 6.09M | 4.04M |
Cash Flow | ||||||
| Free Cash Flow | -320.49K | -706.63K | -1.15M | -4.36M | -2.08M | 675.18K |
| Operating Cash Flow | -309.73K | -706.63K | -1.13M | -3.46M | -1.18M | 1.37M |
| Investing Cash Flow | -22.09K | 5.00K | -17.48K | -902.77K | -778.93K | -428.74K |
| Financing Cash Flow | -356.80K | -10.70K | 982.56K | 240.86K | 3.50M | 3.23M |
Global Health Limited Technical Analysis
Negative
0.09
Price Trends
0.07
Negative
0.07
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
24.35
Positive
10.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GLH, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and above the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 24.35 is Positive, neither overbought nor oversold. The STOCH value of 10.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GLH.
Global Health Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$18.59M | -2.48 | -578.72% | ― | 43.55% | 26.03% | |
44 Neutral | AU$24.89M | -1.71 | -1122.02% | ― | ― | ― | |
43 Neutral | AU$2.24M | -1.11 | -42.29% | ― | ― | -64.67% | |
42 Neutral | AU$7.56M | -0.96 | 152.58% | ― | -57.91% | -9.02% | |
41 Neutral | AU$3.59M | -1.98 | 15.41% | ― | -5.76% | 8.00% | |
41 Neutral | AU$31.46M | -4.21 | -52.26% | ― | 22.81% | -110.26% |
* Healthcare Sector Average
AU:GLH
Global Health Limited
0.06
-0.02
-23.75%
AU:TD1
Tali Digital
0.05
-0.02
-31.43%
AU:PKY
Opyl Ltd.
0.04
0.02
115.79%
AU:EMD
Emyria Ltd
0.04
<0.01
18.18%
AU:HIQ
HitIQ Limited
0.01
-0.01
-52.38%
AU:ICR
InteliCare Holdings Limited
0.03
0.01
85.71%
Global Health Limited Corporate Events
Global Health issues cautionary investor update for H1 FY2026
Mar 25, 2026
Global Health Limited has released an investor presentation for the half year ended 31 December 2025, outlining its activities and financial position as of 23 March 2026. The company stresses that the document is informational only, does not const...
Global Health shifts to high-quality SaaS revenue as recurring income climbs
Feb 25, 2026
Global Health Limited reported that while total customer revenue for the half year to 31 December 2025 declined 1% year on year and 11% over three years, it has significantly reshaped its revenue mix toward higher-quality subscription income. The ...
Global Health Narrows Half-Year Loss as Net Tangible Liabilities Deepen
Feb 25, 2026
Global Health Limited reported half-year revenue of A$3.59 million for the period ended 31 December 2025, a 1.19% decline from the prior corresponding period, and recorded a net loss after tax of A$629,201, slightly improved from the A$686,754 los...
Global Health Issues 150,000 Unquoted Performance Rights Under Incentive Plan
Feb 25, 2026
Global Health Limited has notified the market of the issue of 150,000 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on February 23, 2026, and reflec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.